Patrizia Cavazzoni, leader of the FDA's Center for Drug Evaluation and Research, is leaving the agency on Jan. 18.

The director of the FDA's main drug review office will exit on Jan. 18, according to an email sent to staff. Her departure is ...

The FDA’s influential director of the Center for Drug Evaluation and Research, Patrizia Cavazzoni, M.D., will soon retire ...

Following a string of FDA resignations, Patrizia Cavazzoni has announced that her last day will be 18 January.

FDA's Center for Drug Evaluation and Research director, Patrizia Cavazzoni, MD, to step down in mid-January. Other top leaders also leaving FDA.

"It is the FDA's role to ensure that drugs are safe and effective," said Dr. Patrizia Cavazzoni, director of the FDA's Center ...

we are taking this next step in the process to propose removing oral phenylephrine because it is not effective as a nasal ...

“Based on our review of available data, and consistent with the advice of the advisory committee, we are taking this next step in the process,” said Patrizia Cavazzoni, M.D., director of the FDA’s ...

The FDA recommended patients obtain drugs with "a prescription from their doctor and fill the prescription at a state-licensed pharmacy." Patrizia Cavazzoni, the director of the FDA’s Center for ...

It will be co-led by Patrizia Cavazzoni, director of the FDA's Centre for Drugs Evaluation and Research (CDER), and Centre for Biologics Evaluation and Research (CBER) director Peter Marks.

“It is the FDA’s role to ensure that drugs are safe and effective,” said Patrizia Cavazzoni, MD, director of the agency’s Center for Drug Evaluation and Research (CDER). “Based on our ...

“It is the FDA’s role to ensure that drugs are safe and effective,” Dr. Patrizia Cavazzoni, the director of the FDA’s Center for Drug Evaluation and Research, said in a statement.